Standard Biotools Inc. (LAB) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Standard Biotools reported revenue of $85.3M, down 51.1% from $174.4M the year before. Net income was -$74.9M (a -87.8% net margin), or -$0.20 per diluted share. Gross margin was 49.9% and operating margin was -129.2%. Operating activities generated -$74.3M of cash, leaving -$82.6M of free cash flow. At fiscal year end, Standard Biotools held $567.8M in total assets against $143.5M in total liabilities, including $120.9M of cash and equivalents.
Open the full interactive Standard Biotools financials → Quarterly statements, key ratios, valuation history and price charts.
Standard Biotools Key Stats
| Share Price | $0.66 |
|---|---|
| Market Cap | $258.0M |
| Revenue YoY Growth | -51.1% |
| 52-Week Range | $0.64 – $1.68 |
| Shares Outstanding | 390.9 million (basic, 2026 Q2) |
Standard Biotools Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $138.1M | $130.6M | $97.9M | $106.3M | $174.4M | $85.3M |
| Cost of Goods Sold | $47.5M | $53.3M | $52.6M | $55.9M | $90.2M | $42.8M |
| Gross Profit | $90.6M | $77.3M | $45.4M | $50.5M | $84.3M | $42.5M |
| Operating Income | -$51.0M | -$67.5M | -$116.2M | -$76.6M | -$175.2M | -$110.2M |
| Pre-Tax Income | -$54.1M | -$63.7M | -$192.9M | -$74.2M | -$138.3M | -$96.7M |
| Income Tax | -$1.1M | -$4.4M | -$2.8M | $452,000 | $573,000 | -$37.9M |
| Net Income | -$53.0M | -$59.2M | -$190.1M | -$74.7M | -$138.9M | -$74.9M |
| Diluted EPS | -$0.74 | -$0.78 | -$2.43 | -$0.94 | -$0.52 | -$0.20 |
Standard Biotools Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $19.6M | $3.2M | $21.1M | $20.1M |
| Net Income | -$34.7M | $19.3M | $127.1M | -$26.8M |
| Diluted EPS | -$0.09 | $0.05 | $0.33 | -$0.07 |
Standard Biotools Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $68.5M | $28.5M | $81.3M | $51.7M | $166.7M | $120.9M |
| Current Assets | $117.7M | $72.1M | $208.8M | $158.2M | $375.9M | $454.3M |
| Total Assets | $324.8M | $275.2M | $390.3M | $323.1M | $612.3M | $567.8M |
| Current Liabilities | $54.2M | $49.6M | $43.4M | $109.3M | $65.9M | $108.3M |
| Total Long-Term Debt | $54.2M | $64.2M | $64.9M | $63.5M | $299,000 | $299,000 |
| Total Liabilities | $185.7M | $180.6M | $160.5M | $159.9M | $140.6M | $143.5M |
| Shareholders' Equity | $139.1M | $94.6M | -$81.5M | -$148.1M | $471.7M | $424.3M |
Standard Biotools Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$15.4M | -$44.1M | -$89.4M | -$43.3M | -$143.5M | -$74.3M |
| Cash From Investing | $40.0M | -$11.9M | -$88.1M | $20.2M | $363.2M | $27.4M |
| Cash From Financing | $20.9M | $16.0M | $230.8M | -$6.8M | -$102.6M | $570,000 |
| Free Cash Flow | -$28.1M | -$57.3M | -$93.2M | -$46.1M | -$151.8M | -$82.6M |
Figures from Standard Biotools' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Standard Biotools financials page for every line item.
Standard Biotools Company Profile
| Ticker | LAB |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Boston, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Accelerated filer |
| SEC CIK | 0001162194 |
Frequently Asked Questions
What was Standard Biotools' revenue in fiscal 2025?
Standard Biotools (LAB) reported revenue of $85.3M for fiscal 2025.
What is Standard Biotools' annual revenue history?
Standard Biotools' annual revenue by fiscal year: 2020: $138.1M; 2021: $130.6M; 2022: $97.9M; 2023: $106.3M; 2024: $174.4M; 2025: $85.3M.
What was Standard Biotools' net income in fiscal 2025?
Standard Biotools reported net income of -$74.9M for fiscal 2025.
What was Standard Biotools' earnings per share (EPS) in fiscal 2025?
Standard Biotools' diluted EPS was -$0.20 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Standard Biotools generate in fiscal 2025?
Standard Biotools generated -$82.6M of free cash flow in fiscal 2025.
What was Standard Biotools' revenue last quarter?
In its most recent reported quarter (2026 Q2), Standard Biotools reported revenue of $20.1M.
How much debt does Standard Biotools have?
Standard Biotools reported $299,000 of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Standard Biotools are outstanding?
Standard Biotools reported a weighted average of 390.9 million basic shares outstanding in 2026 Q2.
What is Standard Biotools' market cap?
Based on its latest closing price, Standard Biotools (LAB) has a market capitalization of about $258.0M.
When does Standard Biotools' fiscal year end?
Standard Biotools' fiscal year end, as registered with the SEC, is December 31.
Where is Standard Biotools headquartered?
Standard Biotools lists its business address in Boston, Massachusetts in its SEC filings.